Skip to main content

Dermatology

Daric Mueller, PA-C
@rheumPAC
IIM-ILD patterns and serologies Most common HRCT pattern: NSIP HRCT features: interstitial thickening, GGOs and irregular pleural margins Serology standouts: - MDA5 (+) = high ILD risk - higher HRCT severity scores in MDA5 (+) and Jo-1 (+) Abstract 2599, #ACR26 @RheumNow
Eric Dein
@ericdeinmd
#ACR26 @RheumNow V Werth Supplements & SARD flare -Isalean weight loss powder affects cytokine secretion: TNFa, IFNa, IFNb mediated through TLR4 -Elderberry assoc w exacerbation in DM, CLE Dermatomyositis is incr - Environmental cause? DM pts more likely to flare w supplem v CLE https://t.co/6h72pidaHk

FDA Approves Tildrakizumab for Psoriatic Arthritis

Jack Cush, MD

Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab  (Ilumya) for use in patients with active psoriatic arthritis. This agent is already FDA approved for plaque psoriasis, and joins guselkumab and risankizumab as the third IL-23 inhibitor

Dr. John Cush
@RheumNow
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings Listen to leading rheumatology and dermatology experts for an engaging discussion on the evolving landscape of Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE). https://t.co/lJOzeR81AS

Mixed Drinks, Mixed Results (10.30.2026)

Jack Cush, MD

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis

Novel Imaging of Skin Disease in Scleroderma

MedPage Today

An emerging technique called spatial frequency domain imaging (SFDI) proved its mettle for evaluating skin fibrosis in systemic sclerosis (SSc), also called scleroderma, in an early clinical study.

Don’t Hold the JAK (10.9.2026)

Jack Cush, MD

On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients. 

Dr. John Cush
@RheumNow
DERM on RheumNow PODCAST (September 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors. https://t.co/QYX9G5UFg5
×